| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 5716 | 2019 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2598 | 2019 |
| Long-term use of ticagrelor in patients with prior myocardial infarction MP Bonaca, DL Bhatt, M Cohen, PG Steg, RF Storey, EC Jensen, ... New England Journal of Medicine 372 (19), 1791-1800, 2015 | 2142 | 2015 |
| Vorapaxar in the secondary prevention of atherothrombotic events DA Morrow, E Braunwald, MP Bonaca, SF Ameriso, AJ Dalby, MP Fish, ... New England Journal of Medicine 366 (15), 1404-1413, 2012 | 1107 | 2012 |
| Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ... The Lancet Oncology 19 (12), 1579-1589, 2018 | 849 | 2018 |
| Rivaroxaban in peripheral artery disease after revascularization MP Bonaca, RM Bauersachs, SS Anand, ES Debus, MR Nehler, MR Patel, ... New England Journal of Medicine 382 (21), 1994-2004, 2020 | 736 | 2020 |
| Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular … MP Bonaca, P Nault, RP Giugliano, AC Keech, AL Pineda, E Kanevsky, ... Circulation 137 (4), 338-350, 2018 | 693 | 2018 |
| Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 684 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 613 | 2019 |
| Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial ML O’Donoghue, E Braunwald, HD White, DL Steen, MA Lukas, E Tarka, ... Jama 312 (10), 1006-1015, 2014 | 466 | 2014 |
| Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta … JA Udell, MP Bonaca, JP Collet, AM Lincoff, DJ Kereiakes, F Costa, ... European heart journal 37 (4), 390-399, 2016 | 448 | 2016 |
| Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19 … AC Spyropoulos, M Goldin, D Giannis, W Diab, J Wang, S Khanijo, ... JAMA internal medicine 181 (12), 1612-1620, 2021 | 411 | 2021 |
| Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease MP Bonaca, DL Bhatt, RF Storey, PG Steg, M Cohen, J Kuder, E Goodrich, ... Journal of the American College of Cardiology 67 (23), 2719-2728, 2016 | 406 | 2016 |
| Vorapaxar in patients with peripheral artery disease: results from TRA2° P-TIMI 50 MP Bonaca, BM Scirica, MA Creager, J Olin, H Bounameaux, M Dellborg, ... Circulation 127 (14), 1522-1529, 2013 | 334 | 2013 |
| Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ... Circulation 139 (22), 2516-2527, 2019 | 322 | 2019 |
| Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology MP Bonaca, BA Olenchock, JE Salem, SD Wiviott, S Ederhy, A Cohen, ... Circulation 140 (1), 80-91, 2019 | 319 | 2019 |
| Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial TA Zelniker, MP Bonaca, RHM Furtado, O Mosenzon, JF Kuder, ... Circulation 141 (15), 1227-1234, 2020 | 304 | 2020 |
| Cardiovascular safety of lorcaserin in overweight or obese patients EA Bohula, SD Wiviott, DK McGuire, SE Inzucchi, J Kuder, KA Im, ... New England Journal of Medicine 379 (12), 1107-1117, 2018 | 263 | 2018 |
| Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial BM Scirica, MP Bonaca, E Braunwald, GM De Ferrari, D Isaza, BS Lewis, ... The Lancet 380 (9850), 1317-1324, 2012 | 251 | 2012 |
| Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54 DL Bhatt, MP Bonaca, S Bansilal, DJ Angiolillo, M Cohen, RF Storey, K Im, ... Journal of the American College of Cardiology 67 (23), 2732-2740, 2016 | 241 | 2016 |
Deepak L. Bhatt, MD, MPH, MBADr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount SinaiAdresse e-mail validée de post.harvard.edu
